Drug Trial Radar · NCT05752461
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Apr 12, 2023
Primary completion
Apr 12, 2024
Study completion Jun 25, 2024
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
Conditions
- Prevention of Venous Thromboembolism After Knee Arthroplasty
Interventions
SHR-2004 injectionDrug
low dose subcutaneous injection once
SHR-2004 injectionDrug
medium dose subcutaneous injection once
SHR-2004 injectionDrug
high dose subcutaneous injection once
Enoxaparin sodium injectionDrug
40 mg administered as subcutaneous injection once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Primary efficacy outcome)Time frame: Day 12
- Incidence of composite endpoint of major and clinically relevant non-major bleeding(Primary safety outcome)Time frame: Day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.